To The Moon
Home
News
TigerAI
Log In
Sign Up
Csloke
+Follow
Posts · 64
Posts · 64
Following · 0
Following · 0
Followers · 0
Followers · 0
Csloke
Csloke
·
2021-09-07
Hi
Sorry, this post has been deleted
看
2.32K
回复
1
点赞
4
编组 21备份 2
Share
Report
Csloke
Csloke
·
2021-09-05
Great article
我所理解的價值投資
@旭阳特别帅:
2021年5月16號,我正式從公司辭職了。原因有很多,一個顯而易見的原因當然是公司錢沒給夠,路子給的不夠寬(大實話);一個是賺了不少錢,底氣足了;一個是想去提高自己,留學(這個想了很久了);所以還是想去試試,爲了以後不後悔。 當然你會問,賺這點錢就辭職了?我想說,能賺多少錢就有多少配得上這財富的認知,今年賺完明年就不賺啦?不做人了?我會更加富有,學習型的人潛力無限的。 我現在纔來跟大家聊聊我所理解的價值投資,是因爲資金量上了一個層級。我認爲這種投資理念適合完成一點資本積累的人。因爲資金量少,比如幾萬的,幾千的,翻個10倍也不過幾十萬和幾萬,真的無法對人生做出什麼改變。可能我比較激進,筆者個人覺得資金小的不大適合長線投資。因爲資金小本身持有的時候就會覺得不值得,對於人來說,尤其是年輕人來說,時間就是最大的成本。 價值投資一般的持有周期都以年來算,人生能有幾年?1萬翻100倍到100萬,估計都幾十年過去了,筆者感覺不值得。小資金的宿命,就是要去博,抓住一切大波動,完成資本積累,後面纔有資格來談價值投資。所以價值投資十分適合資金量比較大的,首先資金量大,本身就意味着不急着賺錢了,有更多的耐心陪企業成長,從而正向循環賺到更多的錢,這就是富人的心裏優勢,穿越所有波動週期,關注企業本身產品和利潤。 以上的看法就是我所經歷過的。大學的時候,手裏就家人的賬戶裏的錢搞股票。這段時間剛好遇到股災,也沒有什麼打法,一切都還是陌生的,但我決心認真學學這東西。首先接觸到的就是技術流派,一開始是看同花順軟件裏對於技術指標的說明,什麼時候大概會漲,什麼時候大概會跌,全都是霧裏看花。把軟件倒騰完後,自己買了本股市入門,對中國股市有了初步認知,瞭解到這個市場建立時間還不長,代碼,交易所,結算機制等等。 然後小白就衝進去虧錢了,就是所謂的交學費。一邊交學費,一邊瘋狂看書。後面看的就多了,也知道自己要看什麼書能
我所理解的價值投資
看
2.35K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
Csloke
Csloke
·
2021-09-03
Hi
生日快樂,生日快漲
@积神斗港女:
今天積神生日,收到了兄弟姐妹們的生日禮物和祝福,今年,是自己收到最多禮物的一次生日了,畢竟,我的生日基本上就是開學日,容易遭討厭。這周,可能是生日的紅利吧,自己的操作還算不錯了,但我明白,自己還有很長的路要走,還有很多知識要學習,還得經歷更多。每個時期獲得的快樂源泉都是不一樣的。年幼時期,我的快樂就是天天粘着父母四處玩;學生時期,快樂源於寒暑假的旅遊聚會;留學時期,通宵達旦,那是頭一次離開父母后瘋狂的快樂;工作前期,快樂就只剩下週六日的居家生活;到了現在,每天的快樂就是不斷豐富股票知識,同時還能看着賬戶裏的數字一天天變大,我覺得,這纔是成人的快樂吧。進入股市的初衷,有人是想賺快錢,有人是想獲得穩定的收益改善生活,有人是想財富自由,而我就是想做到財富自由的那位,很異想天開吧?但那時的我是很堅定的相信,股市裏是沒有知識需要學習的,只要有運氣,在股市就能賺到錢,就能夠財富自由!但入場後我才發現,股市遠沒有自己想的那麼簡單,處處是兇險。即便在連續碰壁了之後,我還是沒意識到股市大有學問,沒想到去通過學習來建立自己的認知,建立自己的模式。那時候,我是一點覺悟都沒有的,可以說,如果沒有狗屎運,我現在一定會跑輸絕大部分的人,甚至已經離場,做回那個期待週六日的打工人。不得不說,一年前的狗屎運讓我的人生髮生了翻天覆地的變化,還是往好方向改變的。但這樣的運氣並不是讓我立馬賺到了大錢,成爲暴發戶,但是它,讓我遇到了我師父,教了我很多足以讓我在股市裏終生受用的知識。一切都是那麼的糊里糊塗,卻又那麼的順其自然,或許真的是猿糞吧。以前我對‘知識改變命運’這句話是非常反感的,因爲我學生時代是個學渣,那時候的我並不認爲‘讀死書’可以改變命運。但我錯了,我理解錯了這句話,每當我一次又一次將股市的知識應用到實戰中的時候,才醒悟過來,知識,真好。在實踐當中我獲得了從未有過的充實感和成就感,雖然我還沒能賺多少錢,但
生日快樂,生日快漲
看
2.15K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
Csloke
Csloke
·
2021-09-02
Hi
Sorry, this post has been deleted
看
3.57K
回复
2
点赞
4
编组 21备份 2
Share
Report
Csloke
Csloke
·
2021-09-01
Hi
OPEC+ raises 2022 oil demand growth forecast
LONDON, Sept 1 (Reuters) - The OPEC+ group of oil producers has made an upward revision to its 2022
OPEC+ raises 2022 oil demand growth forecast
看
2.84K
回复
1
点赞
2
编组 21备份 2
Share
Report
Csloke
Csloke
·
2021-08-31
Hi
Sorry, this post has been deleted
看
3.27K
回复
1
点赞
4
编组 21备份 2
Share
Report
Csloke
Csloke
·
2021-08-29
Hi
Sorry, this post has been deleted
看
2.85K
回复
2
点赞
2
编组 21备份 2
Share
Report
Csloke
Csloke
·
2021-08-28
Hi
U.S. resumes supply of Lilly's COVID-19 antibody combo to some states
Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID
U.S. resumes supply of Lilly's COVID-19 antibody combo to some states
看
2.81K
回复
2
点赞
9
编组 21备份 2
Share
Report
Csloke
Csloke
·
2021-08-26
Upupip
看
2.13K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
Csloke
Csloke
·
2021-08-26
Hi
Sorry, this post has been deleted
看
2.83K
回复
1
点赞
5
编组 21备份 2
Share
Report
Load more
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3586671359227798","uuid":"3586671359227798","gmtCreate":1623578871475,"gmtModify":1627103429144,"name":"Csloke","pinyin":"csloke","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/4f4ae1f1b04f4bbad3568e1bc3151189","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":162,"tweetSize":64,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":880042352,"gmtCreate":1631003632576,"gmtModify":1676530439676,"author":{"id":"3586671359227798","authorId":"3586671359227798","name":"Csloke","avatar":"https://static.tigerbbs.com/4f4ae1f1b04f4bbad3568e1bc3151189","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586671359227798","idStr":"3586671359227798"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/880042352","repostId":"1187080413","repostType":4,"isVote":1,"tweetType":1,"viewCount":2316,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":814256374,"gmtCreate":1630830705398,"gmtModify":1676530402827,"author":{"id":"3586671359227798","authorId":"3586671359227798","name":"Csloke","avatar":"https://static.tigerbbs.com/4f4ae1f1b04f4bbad3568e1bc3151189","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586671359227798","idStr":"3586671359227798"},"themes":[],"htmlText":"Great article","listText":"Great article","text":"Great article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/814256374","repostId":"815987527","repostType":1,"repost":{"id":815987527,"gmtCreate":1630635978969,"gmtModify":1676530362523,"author":{"id":"3434046638438343","authorId":"3434046638438343","name":"旭阳特别帅","avatar":"https://static.laohu8.com/bbe12234effaffbb31106d837a04c53f","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3434046638438343","idStr":"3434046638438343"},"themes":[],"title":"我所理解的價值投資","htmlText":"2021年5月16號,我正式從公司辭職了。原因有很多,一個顯而易見的原因當然是公司錢沒給夠,路子給的不夠寬(大實話);一個是賺了不少錢,底氣足了;一個是想去提高自己,留學(這個想了很久了);所以還是想去試試,爲了以後不後悔。 當然你會問,賺這點錢就辭職了?我想說,能賺多少錢就有多少配得上這財富的認知,今年賺完明年就不賺啦?不做人了?我會更加富有,學習型的人潛力無限的。 我現在纔來跟大家聊聊我所理解的價值投資,是因爲資金量上了一個層級。我認爲這種投資理念適合完成一點資本積累的人。因爲資金量少,比如幾萬的,幾千的,翻個10倍也不過幾十萬和幾萬,真的無法對人生做出什麼改變。可能我比較激進,筆者個人覺得資金小的不大適合長線投資。因爲資金小本身持有的時候就會覺得不值得,對於人來說,尤其是年輕人來說,時間就是最大的成本。 價值投資一般的持有周期都以年來算,人生能有幾年?1萬翻100倍到100萬,估計都幾十年過去了,筆者感覺不值得。小資金的宿命,就是要去博,抓住一切大波動,完成資本積累,後面纔有資格來談價值投資。所以價值投資十分適合資金量比較大的,首先資金量大,本身就意味着不急着賺錢了,有更多的耐心陪企業成長,從而正向循環賺到更多的錢,這就是富人的心裏優勢,穿越所有波動週期,關注企業本身產品和利潤。 以上的看法就是我所經歷過的。大學的時候,手裏就家人的賬戶裏的錢搞股票。這段時間剛好遇到股災,也沒有什麼打法,一切都還是陌生的,但我決心認真學學這東西。首先接觸到的就是技術流派,一開始是看同花順軟件裏對於技術指標的說明,什麼時候大概會漲,什麼時候大概會跌,全都是霧裏看花。把軟件倒騰完後,自己買了本股市入門,對中國股市有了初步認知,瞭解到這個市場建立時間還不長,代碼,交易所,結算機制等等。 然後小白就衝進去虧錢了,就是所謂的交學費。一邊交學費,一邊瘋狂看書。後面看的就多了,也知道自己要看什麼書能","listText":"2021年5月16號,我正式從公司辭職了。原因有很多,一個顯而易見的原因當然是公司錢沒給夠,路子給的不夠寬(大實話);一個是賺了不少錢,底氣足了;一個是想去提高自己,留學(這個想了很久了);所以還是想去試試,爲了以後不後悔。 當然你會問,賺這點錢就辭職了?我想說,能賺多少錢就有多少配得上這財富的認知,今年賺完明年就不賺啦?不做人了?我會更加富有,學習型的人潛力無限的。 我現在纔來跟大家聊聊我所理解的價值投資,是因爲資金量上了一個層級。我認爲這種投資理念適合完成一點資本積累的人。因爲資金量少,比如幾萬的,幾千的,翻個10倍也不過幾十萬和幾萬,真的無法對人生做出什麼改變。可能我比較激進,筆者個人覺得資金小的不大適合長線投資。因爲資金小本身持有的時候就會覺得不值得,對於人來說,尤其是年輕人來說,時間就是最大的成本。 價值投資一般的持有周期都以年來算,人生能有幾年?1萬翻100倍到100萬,估計都幾十年過去了,筆者感覺不值得。小資金的宿命,就是要去博,抓住一切大波動,完成資本積累,後面纔有資格來談價值投資。所以價值投資十分適合資金量比較大的,首先資金量大,本身就意味着不急着賺錢了,有更多的耐心陪企業成長,從而正向循環賺到更多的錢,這就是富人的心裏優勢,穿越所有波動週期,關注企業本身產品和利潤。 以上的看法就是我所經歷過的。大學的時候,手裏就家人的賬戶裏的錢搞股票。這段時間剛好遇到股災,也沒有什麼打法,一切都還是陌生的,但我決心認真學學這東西。首先接觸到的就是技術流派,一開始是看同花順軟件裏對於技術指標的說明,什麼時候大概會漲,什麼時候大概會跌,全都是霧裏看花。把軟件倒騰完後,自己買了本股市入門,對中國股市有了初步認知,瞭解到這個市場建立時間還不長,代碼,交易所,結算機制等等。 然後小白就衝進去虧錢了,就是所謂的交學費。一邊交學費,一邊瘋狂看書。後面看的就多了,也知道自己要看什麼書能","text":"2021年5月16號,我正式從公司辭職了。原因有很多,一個顯而易見的原因當然是公司錢沒給夠,路子給的不夠寬(大實話);一個是賺了不少錢,底氣足了;一個是想去提高自己,留學(這個想了很久了);所以還是想去試試,爲了以後不後悔。 當然你會問,賺這點錢就辭職了?我想說,能賺多少錢就有多少配得上這財富的認知,今年賺完明年就不賺啦?不做人了?我會更加富有,學習型的人潛力無限的。 我現在纔來跟大家聊聊我所理解的價值投資,是因爲資金量上了一個層級。我認爲這種投資理念適合完成一點資本積累的人。因爲資金量少,比如幾萬的,幾千的,翻個10倍也不過幾十萬和幾萬,真的無法對人生做出什麼改變。可能我比較激進,筆者個人覺得資金小的不大適合長線投資。因爲資金小本身持有的時候就會覺得不值得,對於人來說,尤其是年輕人來說,時間就是最大的成本。 價值投資一般的持有周期都以年來算,人生能有幾年?1萬翻100倍到100萬,估計都幾十年過去了,筆者感覺不值得。小資金的宿命,就是要去博,抓住一切大波動,完成資本積累,後面纔有資格來談價值投資。所以價值投資十分適合資金量比較大的,首先資金量大,本身就意味着不急着賺錢了,有更多的耐心陪企業成長,從而正向循環賺到更多的錢,這就是富人的心裏優勢,穿越所有波動週期,關注企業本身產品和利潤。 以上的看法就是我所經歷過的。大學的時候,手裏就家人的賬戶裏的錢搞股票。這段時間剛好遇到股災,也沒有什麼打法,一切都還是陌生的,但我決心認真學學這東西。首先接觸到的就是技術流派,一開始是看同花順軟件裏對於技術指標的說明,什麼時候大概會漲,什麼時候大概會跌,全都是霧裏看花。把軟件倒騰完後,自己買了本股市入門,對中國股市有了初步認知,瞭解到這個市場建立時間還不長,代碼,交易所,結算機制等等。 然後小白就衝進去虧錢了,就是所謂的交學費。一邊交學費,一邊瘋狂看書。後面看的就多了,也知道自己要看什麼書能","images":[{"img":"https://static.tigerbbs.com/05265ddbdc34f1a48cf2b5648ad9a676","width":"1280","height":"720"},{"img":"https://static.tigerbbs.com/86221bc91ad73af990a29462b1d4a271","width":"960","height":"600"},{"img":"https://static.tigerbbs.com/038c03732548542d18d53a77df0c2c1a","width":"1280","height":"616"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815987527","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":4,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2348,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":815609213,"gmtCreate":1630672026932,"gmtModify":1676530372027,"author":{"id":"3586671359227798","authorId":"3586671359227798","name":"Csloke","avatar":"https://static.tigerbbs.com/4f4ae1f1b04f4bbad3568e1bc3151189","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586671359227798","idStr":"3586671359227798"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/815609213","repostId":"812524811","repostType":1,"repost":{"id":812524811,"gmtCreate":1630595878333,"gmtModify":1676530352770,"author":{"id":"3554550096616171","authorId":"3554550096616171","name":"积神斗港女","avatar":"https://static.tigerbbs.com/dd40978fab43740b55a115239a8b1d29","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3554550096616171","idStr":"3554550096616171"},"themes":[],"title":"生日快樂,生日快漲","htmlText":"今天積神生日,收到了兄弟姐妹們的生日禮物和祝福,今年,是自己收到最多禮物的一次生日了,畢竟,我的生日基本上就是開學日,容易遭討厭。這周,可能是生日的紅利吧,自己的操作還算不錯了,但我明白,自己還有很長的路要走,還有很多知識要學習,還得經歷更多。每個時期獲得的快樂源泉都是不一樣的。年幼時期,我的快樂就是天天粘着父母四處玩;學生時期,快樂源於寒暑假的旅遊聚會;留學時期,通宵達旦,那是頭一次離開父母后瘋狂的快樂;工作前期,快樂就只剩下週六日的居家生活;到了現在,每天的快樂就是不斷豐富股票知識,同時還能看着賬戶裏的數字一天天變大,我覺得,這纔是成人的快樂吧。進入股市的初衷,有人是想賺快錢,有人是想獲得穩定的收益改善生活,有人是想財富自由,而我就是想做到財富自由的那位,很異想天開吧?但那時的我是很堅定的相信,股市裏是沒有知識需要學習的,只要有運氣,在股市就能賺到錢,就能夠財富自由!但入場後我才發現,股市遠沒有自己想的那麼簡單,處處是兇險。即便在連續碰壁了之後,我還是沒意識到股市大有學問,沒想到去通過學習來建立自己的認知,建立自己的模式。那時候,我是一點覺悟都沒有的,可以說,如果沒有狗屎運,我現在一定會跑輸絕大部分的人,甚至已經離場,做回那個期待週六日的打工人。不得不說,一年前的狗屎運讓我的人生髮生了翻天覆地的變化,還是往好方向改變的。但這樣的運氣並不是讓我立馬賺到了大錢,成爲暴發戶,但是它,讓我遇到了我師父,教了我很多足以讓我在股市裏終生受用的知識。一切都是那麼的糊里糊塗,卻又那麼的順其自然,或許真的是猿糞吧。以前我對‘知識改變命運’這句話是非常反感的,因爲我學生時代是個學渣,那時候的我並不認爲‘讀死書’可以改變命運。但我錯了,我理解錯了這句話,每當我一次又一次將股市的知識應用到實戰中的時候,才醒悟過來,知識,真好。在實踐當中我獲得了從未有過的充實感和成就感,雖然我還沒能賺多少錢,但","listText":"今天積神生日,收到了兄弟姐妹們的生日禮物和祝福,今年,是自己收到最多禮物的一次生日了,畢竟,我的生日基本上就是開學日,容易遭討厭。這周,可能是生日的紅利吧,自己的操作還算不錯了,但我明白,自己還有很長的路要走,還有很多知識要學習,還得經歷更多。每個時期獲得的快樂源泉都是不一樣的。年幼時期,我的快樂就是天天粘着父母四處玩;學生時期,快樂源於寒暑假的旅遊聚會;留學時期,通宵達旦,那是頭一次離開父母后瘋狂的快樂;工作前期,快樂就只剩下週六日的居家生活;到了現在,每天的快樂就是不斷豐富股票知識,同時還能看着賬戶裏的數字一天天變大,我覺得,這纔是成人的快樂吧。進入股市的初衷,有人是想賺快錢,有人是想獲得穩定的收益改善生活,有人是想財富自由,而我就是想做到財富自由的那位,很異想天開吧?但那時的我是很堅定的相信,股市裏是沒有知識需要學習的,只要有運氣,在股市就能賺到錢,就能夠財富自由!但入場後我才發現,股市遠沒有自己想的那麼簡單,處處是兇險。即便在連續碰壁了之後,我還是沒意識到股市大有學問,沒想到去通過學習來建立自己的認知,建立自己的模式。那時候,我是一點覺悟都沒有的,可以說,如果沒有狗屎運,我現在一定會跑輸絕大部分的人,甚至已經離場,做回那個期待週六日的打工人。不得不說,一年前的狗屎運讓我的人生髮生了翻天覆地的變化,還是往好方向改變的。但這樣的運氣並不是讓我立馬賺到了大錢,成爲暴發戶,但是它,讓我遇到了我師父,教了我很多足以讓我在股市裏終生受用的知識。一切都是那麼的糊里糊塗,卻又那麼的順其自然,或許真的是猿糞吧。以前我對‘知識改變命運’這句話是非常反感的,因爲我學生時代是個學渣,那時候的我並不認爲‘讀死書’可以改變命運。但我錯了,我理解錯了這句話,每當我一次又一次將股市的知識應用到實戰中的時候,才醒悟過來,知識,真好。在實踐當中我獲得了從未有過的充實感和成就感,雖然我還沒能賺多少錢,但","text":"今天積神生日,收到了兄弟姐妹們的生日禮物和祝福,今年,是自己收到最多禮物的一次生日了,畢竟,我的生日基本上就是開學日,容易遭討厭。這周,可能是生日的紅利吧,自己的操作還算不錯了,但我明白,自己還有很長的路要走,還有很多知識要學習,還得經歷更多。每個時期獲得的快樂源泉都是不一樣的。年幼時期,我的快樂就是天天粘着父母四處玩;學生時期,快樂源於寒暑假的旅遊聚會;留學時期,通宵達旦,那是頭一次離開父母后瘋狂的快樂;工作前期,快樂就只剩下週六日的居家生活;到了現在,每天的快樂就是不斷豐富股票知識,同時還能看着賬戶裏的數字一天天變大,我覺得,這纔是成人的快樂吧。進入股市的初衷,有人是想賺快錢,有人是想獲得穩定的收益改善生活,有人是想財富自由,而我就是想做到財富自由的那位,很異想天開吧?但那時的我是很堅定的相信,股市裏是沒有知識需要學習的,只要有運氣,在股市就能賺到錢,就能夠財富自由!但入場後我才發現,股市遠沒有自己想的那麼簡單,處處是兇險。即便在連續碰壁了之後,我還是沒意識到股市大有學問,沒想到去通過學習來建立自己的認知,建立自己的模式。那時候,我是一點覺悟都沒有的,可以說,如果沒有狗屎運,我現在一定會跑輸絕大部分的人,甚至已經離場,做回那個期待週六日的打工人。不得不說,一年前的狗屎運讓我的人生髮生了翻天覆地的變化,還是往好方向改變的。但這樣的運氣並不是讓我立馬賺到了大錢,成爲暴發戶,但是它,讓我遇到了我師父,教了我很多足以讓我在股市裏終生受用的知識。一切都是那麼的糊里糊塗,卻又那麼的順其自然,或許真的是猿糞吧。以前我對‘知識改變命運’這句話是非常反感的,因爲我學生時代是個學渣,那時候的我並不認爲‘讀死書’可以改變命運。但我錯了,我理解錯了這句話,每當我一次又一次將股市的知識應用到實戰中的時候,才醒悟過來,知識,真好。在實踐當中我獲得了從未有過的充實感和成就感,雖然我還沒能賺多少錢,但","images":[{"img":"https://static.tigerbbs.com/b158a69a796d5459d92bf85689f3689d","width":"397","height":"379"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/812524811","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":812615457,"gmtCreate":1630582352279,"gmtModify":1676530346544,"author":{"id":"3586671359227798","authorId":"3586671359227798","name":"Csloke","avatar":"https://static.tigerbbs.com/4f4ae1f1b04f4bbad3568e1bc3151189","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586671359227798","idStr":"3586671359227798"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/812615457","repostId":"2164841727","repostType":4,"isVote":1,"tweetType":1,"viewCount":3573,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":816813875,"gmtCreate":1630486091597,"gmtModify":1676530316888,"author":{"id":"3586671359227798","authorId":"3586671359227798","name":"Csloke","avatar":"https://static.tigerbbs.com/4f4ae1f1b04f4bbad3568e1bc3151189","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586671359227798","idStr":"3586671359227798"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/816813875","repostId":"2164817895","repostType":4,"repost":{"id":"2164817895","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630482993,"share":"https://ttm.financial/m/news/2164817895?lang=&edition=fundamental","pubTime":"2021-09-01 15:56","market":"fut","language":"en","title":"OPEC+ raises 2022 oil demand growth forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2164817895","media":"Reuters","summary":"LONDON, Sept 1 (Reuters) - The OPEC+ group of oil producers has made an upward revision to its 2022 ","content":"<p>LONDON, Sept 1 (Reuters) - The OPEC+ group of oil producers has made an upward revision to its 2022 oil demand forecast ahead of a meeting on Wednesday as the group faces pressure from the United States to raise output more quicker to help to support the global economy.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> OPEC+ sources said the group's experts have revised its 2022 oil demand growth forecast to 4.2 million barrels per day (bpd), up from the previous forecast of 3.28 million bpd.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OPEC+ raises 2022 oil demand growth forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOPEC+ raises 2022 oil demand growth forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-01 15:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Sept 1 (Reuters) - The OPEC+ group of oil producers has made an upward revision to its 2022 oil demand forecast ahead of a meeting on Wednesday as the group faces pressure from the United States to raise output more quicker to help to support the global economy.</p>\n<p><a href=\"https://laohu8.com/S/TWOA.U\">Two</a> OPEC+ sources said the group's experts have revised its 2022 oil demand growth forecast to 4.2 million barrels per day (bpd), up from the previous forecast of 3.28 million bpd.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DDG":"ProShares做空石油与天然气ETF","UCO":"二倍做多彭博原油ETF","USO":"美国原油ETF","DWT":"三倍做空原油ETN","SCO":"二倍做空彭博原油指数ETF","DUG":"二倍做空石油与天然气ETF(ProShares)"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2164817895","content_text":"LONDON, Sept 1 (Reuters) - The OPEC+ group of oil producers has made an upward revision to its 2022 oil demand forecast ahead of a meeting on Wednesday as the group faces pressure from the United States to raise output more quicker to help to support the global economy.\nTwo OPEC+ sources said the group's experts have revised its 2022 oil demand growth forecast to 4.2 million barrels per day (bpd), up from the previous forecast of 3.28 million bpd.","news_type":1,"symbols_score_info":{"DDG":0.9,"UCO":0.9,"DUG":0.9,"USO":0.9,"CLmain":0.9,"DWT":0.9,"SCO":0.9,"BZmain":0.9,"QMmain":0.9}},"isVote":1,"tweetType":1,"viewCount":2843,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":818416702,"gmtCreate":1630425443906,"gmtModify":1676530301266,"author":{"id":"3586671359227798","authorId":"3586671359227798","name":"Csloke","avatar":"https://static.tigerbbs.com/4f4ae1f1b04f4bbad3568e1bc3151189","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586671359227798","idStr":"3586671359227798"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818416702","repostId":"1173998132","repostType":4,"isVote":1,"tweetType":1,"viewCount":3271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813584270,"gmtCreate":1630215380090,"gmtModify":1676530245464,"author":{"id":"3586671359227798","authorId":"3586671359227798","name":"Csloke","avatar":"https://static.tigerbbs.com/4f4ae1f1b04f4bbad3568e1bc3151189","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586671359227798","idStr":"3586671359227798"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/813584270","repostId":"2163304079","repostType":4,"isVote":1,"tweetType":1,"viewCount":2849,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":813142650,"gmtCreate":1630159472570,"gmtModify":1676530236233,"author":{"id":"3586671359227798","authorId":"3586671359227798","name":"Csloke","avatar":"https://static.tigerbbs.com/4f4ae1f1b04f4bbad3568e1bc3151189","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586671359227798","idStr":"3586671359227798"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/813142650","repostId":"2162707824","repostType":4,"repost":{"id":"2162707824","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1630104635,"share":"https://ttm.financial/m/news/2162707824?lang=&edition=fundamental","pubTime":"2021-08-28 06:50","market":"us","language":"en","title":"U.S. resumes supply of Lilly's COVID-19 antibody combo to some states","url":"https://stock-news.laohu8.com/highlight/detail?id=2162707824","media":"Reuters","summary":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID","content":"<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. resumes supply of Lilly's COVID-19 antibody combo to some states</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. resumes supply of Lilly's COVID-19 antibody combo to some states\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-28 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.</p>\n<p>The Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.</p>\n<p>With the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said</p>\n<p>Based on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.</p>\n<p>The department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.</p>\n<p>The supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.</p>\n<p>Regeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's</p>\n<p>sotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.</p>\n<p>Bamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LLY":"礼来","REGN":"再生元制药公司","VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2162707824","content_text":"Aug 27 (Reuters) - U.S. health officials on Friday decided to resume the supply of Eli Lilly's COVID-19 antibody cocktail to states where variants resistant to it are low, saying the therapy could work against the fast-spreading Delta variant based on lab studies.\nThe Department of Health and Human Services narrowed the scope of authorization for the dual-antibody therapy, bamlanivimab and etesevimab, to states including Colorado, Connecticut and Illinois, Indiana.\nWith the Delta variant becoming the dominant strain, the prevalence of variants resistant to the therapy is steadily decreasing, the agency said\nBased on lab tests, the drugs administered together are expected to retain activity against the Delta variant, but not against Delta plus and variants first identified in Brazil, South Africa and Colombia, it said.\nThe department had in June paused its distribution after the therapy failed to show effectiveness against the coronavirus variants that were first identified in Brazil and South Africa.\nThe supply of standalone etesevimab to be paired with existing supply of bamlanivimab is also being resumed to some states.\nRegeneron's antibody therapy REGEN-COV, and GlaxoSmithKline Plc and partner Vir Biotechnology's\nsotrovimab may be used in all states, territories, and U.S. jurisdictions as they are likely to be effective against most variants including Delta, the agency said.\nBamlanivimab and etesevimab, REGEN-COV and sotrovimab are authorized for use in people 12 years and above with mild-to-moderate infection and are at high risk for progression to severe COVID-19.","news_type":1,"symbols_score_info":{"LLY":0.9,"REGN":0.9,"VIR":0.9}},"isVote":1,"tweetType":1,"viewCount":2814,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":810177236,"gmtCreate":1629958117725,"gmtModify":1676530184160,"author":{"id":"3586671359227798","authorId":"3586671359227798","name":"Csloke","avatar":"https://static.tigerbbs.com/4f4ae1f1b04f4bbad3568e1bc3151189","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586671359227798","idStr":"3586671359227798"},"themes":[],"htmlText":"Upupip","listText":"Upupip","text":"Upupip","images":[{"img":"https://static.tigerbbs.com/a57df60083fad2d95b6158dc3ae8e569","width":"1125","height":"2711"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/810177236","isVote":1,"tweetType":1,"viewCount":2129,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":810174768,"gmtCreate":1629958051754,"gmtModify":1676530184156,"author":{"id":"3586671359227798","authorId":"3586671359227798","name":"Csloke","avatar":"https://static.tigerbbs.com/4f4ae1f1b04f4bbad3568e1bc3151189","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586671359227798","idStr":"3586671359227798"},"themes":[],"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/810174768","repostId":"1197778368","repostType":4,"isVote":1,"tweetType":1,"viewCount":2826,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}